Spectrum Pharmaceuticals (SPPI) Given News Impact Rating of 0.02
Media headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.9685491005847 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Worth Watching Stocks Alert: Arrowhead Pharmaceuticals, Inc., (NASDAQ: ARWR), Spectrum Pharmaceuticals, Inc … – Stocks In The News (press release) (tradingnewsnow.com)
- Spectrum Doubles in 3 Months: What’s Driving the Rally? (finance.yahoo.com)
- Analysts’ Report Recap: Spectrum Pharma Inc (SPPI) – ExpertGazette (expertgazette.com)
- Spectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
Spectrum Pharmaceuticals (NASDAQ SPPI) opened at $19.60 on Friday. Spectrum Pharmaceuticals has a 52-week low of $3.85 and a 52-week high of $21.95. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.04 and a quick ratio of 4.89.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06). The firm had revenue of $36.40 million during the quarter, compared to the consensus estimate of $33.27 million. Spectrum Pharmaceuticals had a negative return on equity of 29.73% and a negative net margin of 58.94%. Spectrum Pharmaceuticals’s revenue was up 9.0% on a year-over-year basis. During the same period last year, the business earned ($0.07) EPS. analysts expect that Spectrum Pharmaceuticals will post -1.03 EPS for the current year.
Several research firms have recently weighed in on SPPI. Guggenheim started coverage on shares of Spectrum Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $32.00 price objective on the stock. ValuEngine upgraded shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Spectrum Pharmaceuticals in a research report on Wednesday, August 16th. Zacks Investment Research upgraded shares of Spectrum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Wednesday, August 9th. Finally, Jefferies Group lifted their target price on shares of Spectrum Pharmaceuticals to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Spectrum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $21.40.
COPYRIGHT VIOLATION WARNING: “Spectrum Pharmaceuticals (SPPI) Given News Impact Rating of 0.02” was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/12/01/spectrum-pharmaceuticals-sppi-given-news-impact-rating-of-0-02.html.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.